Bernhard LÃ¤mmle

List of Publications by Year
in descending order

277 papers	17,992 citations	18482 62 h-index	14208 128 g-index
282 all docs	282 docs citations	282 times ranked	9516 citing authors

#	Article	IF	Citations
1	Definite diagnosis of plasma prekallikrein deficiency should not be based exclusively on shortening of the aPTT upon prolonged preâ€incubation. International Journal of Laboratory Hematology, 2022, 44, .	1.3	2
2	A third form of thrombotic thrombocytopenic purpura?. Haematologica, 2022, , .	3.5	0
3	c.451dupT in KLKB1 is common in Nigerians, confirming a higher prevalence of severe prekallikrein deficiency in Africans compared to Europeans. Journal of Thrombosis and Haemostasis, 2021, 19, 147-152.	3.8	7
4	Immunogenic hotspots in the spacer domain of ADAMTS13 in immuneâ€mediated thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2021, 19, 478-488.	3.8	16
5	Endothelial Dysfunction, Atherosclerosis, and Increase of Von Willebrand Factor and Factor VIII: A Randomized Controlled Trial in Swine. Thrombosis and Haemostasis, 2021, 121, 552-552.	3.4	0
6	Influence of Personality, Resilience and Life Conditions on Depression and Anxiety in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura. Journal of Clinical Medicine, 2021, 10, 365.	2.4	8
7	Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. Journal of Clinical Medicine, 2021, 10, 536.	2.4	94
8	No Evidence for Classic Thrombotic Microangiopathy in COVID-19. Journal of Clinical Medicine, 2021, 10, 671.	2.4	9
9	Diagnosis of Hereditary TTP Caused by Homozygosity for a Rare Complex ADAMTS13 Allele After Salmonella Infection in a 43-Year-Old Asylum Seeker. Frontiers in Medicine, 2021, 8, 639441.	2.6	3
10	Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura. EJHaem, 2021, 2, 188-195.	1.0	1
11	Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861.	1.4	103
12	Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood, 2021, 137, 3563-3575.	1.4	31
13	Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research. Thrombosis Research, 2021, 204, 141-142.	1.7	2
14	Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura. Blood Advances, 2021, 5, 3427-3435.	5.2	16
15	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
16	Stealth thrombosis of brain and kidney in a girl with Upshawâ€“Schulman syndrome not receiving prophylactic plasma infusions. International Journal of Hematology, 2020, 112, 603-604.	1.6	2
17	Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies. Hamostaseologie, 2020, 40, 414-419.	1.9	2
18	The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial. Scientific Reports, 2020, 10, 14219.	3.3	13

#	Article	IF	Citations
19	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood, 2020, 136, 353-361.	1.4	35
20	Severe plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1 mutations, and estimated prevalence. Journal of Thrombosis and Haemostasis, 2020, 18, 1598-1617.	3.8	23
21	Severe COVID-19 infection associated with endothelial activation. Thrombosis Research, 2020, 190, 62.	1.7	358
22	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis, 2020, 120, 538-564.	3.4	64
23	Animal models of thrombotic thrombocytopenic purpura: the tales from zebrafish. Haematologica, 2020, 105, 861-863.	3.5	5
24	ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients. Thrombosis Research, 2020, 192, 174-175.	1.7	66
25	Risk stratification of elderly patients with acute pulmonary embolism. European Journal of Clinical Investigation, 2019, 49, e13154.	3.4	3
26	Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy: Pathophysiology and Differentiation from Graft versus Host Disease. Thrombosis and Haemostasis, 2019, 119, 1382-1382.	3.4	2
27	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica, 2019, 104, 2107-2115.	3.5	99
28	Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome. Blood Advances, 2019, 3, 3191-3195.	5.2	18
29	Standardized Management Protocol in Severe Postpartum Hemorrhage: A Single-Center Study. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 884-893.	1.7	9
30	Predictors and Outcomes of Recurrent Venous Thromboembolism in Elderly Patients. American Journal of Medicine, 2018, 131, 703.e7-703.e16.	1.5	17
31	Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab. Thrombosis and Haemostasis, 2018, 118, 1743-1751.	3.4	31
32	Circulating extracellular DNA is an independent predictor of mortality in elderly patients with venous thromboembolism. PLoS ONE, 2018, 13, e0191150.	2.5	30
33	Hemophagocytic Lymphohistiocytosis in Early Infancy- Pitfall of Differentiation between Hereditary and Infectious Reasons. Blood, 2018, 132, 4961-4961.	1.4	2
34	Detection and Differential Diagnosis of Prekallikrein Deficiency: Genetic Study of New Families and Systematic Review of the Literature. Blood, 2018, 132, 2496-2496.	1.4	0
35	Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients. Blood, 2018, 132, 376-376.	1.4	1
36	Opana ERâ€“induced thrombotic microangiopathy. Blood, 2017, 129, 808-809.	1.4	3

#	Article	IF	Citations
37	Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?. American Journal of Medicine, 2017, 130, 1220.e17-1220.e22.	1.5	11
38	Gut microbiota regulate hepatic von Willebrand factor synthesis and arterial thrombus formation via Toll-like receptor-2. Blood, 2017, 130, 542-553.	1.4	119
39	Depression and cognitive deficits as longâ€term consequences of thrombotic thrombocytopenic purpura. Transfusion, 2017, 57, 1152-1162.	1.6	40
40	Thrombotic thrombocytopenic purpura. Nature Reviews Disease Primers, 2017, 3, 17020.	30.5	242
41	Predictors and Causes of Long-Term Mortality in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. American Journal of Medicine, 2017, 130, 198-206.	1.5	78
42	Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2017, 15, 312-322.	3.8	362
43	Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation. Thrombosis and Haemostasis, 2017, 117, 1930-1936.	3.4	16
44	May-Thurner syndrome: missed diagnosis and missed early treatment?. Hamostaseologie, 2017, 37, 184-185.	1.9	3
45	Association between thyroid dysfunction and venous thromboembolism in the elderly: a prospective cohort study. Journal of Thrombosis and Haemostasis, 2016, 14, 685-694.	3.8	16
46	Caplacizumab accelerates resolution of acute acquired TTP. Nature Reviews Nephrology, 2016, 12, 259-260.	9.6	4
47	High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. Journal of Thrombosis and Haemostasis, 2016, 14, 73-82.	3.8	49
48	Thromboembolism in patients with congenital afibrinogenaemia. Thrombosis and Haemostasis, 2016, 116, 722-732.	3.4	32
49	Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency. International Journal of Hematology, 2016, 103, 283-291.	1.6	20
50	Anticoagulation Management Practices and Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Clinical Research Study. PLoS ONE, 2016, 11, e0148348.	2.5	10
51	VWF and complement. Blood, 2015, 125, 896-898.	1.4	0
52	Depressive Symptoms as a Novel Risk Factor for Recurrent Venous Thromboembolism: A Longitudinal Observational Study in Patients Referred for Thrombophilia Investigation. PLoS ONE, 2015, 10, e0125858.	2.5	15
53	Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. Journal of NeuroVirology, 2015, 21, 694-701.	2.1	22
54	Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy. Thrombosis Research, 2015, 135, S30-S33.	1.7	32

#	Article	IF	Citations
55	ADAMTS13 gene variants and function in women with preeclampsia: A population- based nested case-control study from the HUNT Study. Thrombosis Research, 2015, 136, 282-288.	1.7	7
56	Impaired DNase1â€mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2015, 13, 732-742.	3.8	109
57	Polypharmacy is Associated with an Increased Risk of Bleeding in Elderly Patients with Venous Thromboembolism. Journal of General Internal Medicine, 2015, 30, 17-24.	2.6	64
58	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614.	2.5	4
59	Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura. Hamostaseologie, 2014, 34, 244-248.	1.9	6
60	Bilateral periorbital ecchymoses. Hamostaseologie, 2014, 34, 249-252.	1.9	20
61	The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications. Thrombosis and Haemostasis, 2014, 111, 1180-1183.	3.4	23
62	Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the <scp>ADAMTS</scp>13 gene. European Journal of Haematology, 2014, 92, 168-171.	2.2	10
63	InÂvitro rescue of FGA deletion by lentiviral transduction of an afibrinogenemic patient's hepatocytes. Journal of Thrombosis and Haemostasis, 2014, 12, 1874-1879.	3.8	4
64	Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood, 2014, 123, 1674-1680.	1.4	61
65	The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. Blood, 2014, 124, 3469-3479.	1.4	40
66	Design and establishment of a biobank in a multicenter prospective cohort study of elderly patients with venous thromboembolism (SWITCO65+). Journal of Thrombosis and Thrombolysis, 2013, 36, 484-491.	2.1	11
67	The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. Journal of Thrombosis and Thrombolysis, 2013, 36, 475-483.	2.1	63
68	Plasma DNA is elevated in patients with deep vein thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2013, 1, 341-348.e1.	1.6	99
69	Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood, 2013, 122, 2023-2029.	1.4	161
70	Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. Hamostaseologie, 2013, 33, 138-143.	1.9	43
71	Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica, 2012, 97, 89-97.	3.5	63
72	Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica, 2012, 97, 297-303.	3.5	69

#	Article	IF	Citations
73	Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. Presse Medicale, 2012, 41, e177-e188.	1.9	35
74	Prospective comparison of clinical prognostic scores in elder patients with a pulmonary embolism. Journal of Thrombosis and Haemostasis, 2012, 10, 2270-2276.	3.8	29
75	Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood, 2012, 120, 1157-1164.	1.4	249
76	Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpuraâ€hemolytic uremic syndrome, 1996 to 2011 (CME). Transfusion, 2012, 52, 2525-2532.	1.6	63
77	Initial experience from a doubleâ€blind, placeboâ€controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. American Journal of Hematology, 2012, 87, 430-432.	4.1	71
78	Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology American Society of Hematology Education Program, 2012, 2012, 610-6.	2.5	21
79	Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematology American Society of Hematology Education Program, 2012, 2012, 610-616.	2.5	58
80	Severe Depression Following Recovery From Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2012, 120, 366-366.	1.4	8
81	International Registry for Patients with Hereditary Thrombotic Thrombocytopenic Purpura (TTP) â€“ Upshaw-Schulman Syndrome. Blood, 2012, 120, 4654-4654.	1.4	1
82	Mortality and Morbidities During Long-Term Follow-up After Recovery From Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2012, 120, 362-362.	1.4	1
83	Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: Another case of factor IX propeptide mutation. Thrombosis and Haemostasis, 2011, 106, 381-382.	3.4	5
84	von Willebrand factorâ€“mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood, 2011, 117, 1400-1407.	1.4	369
85	On the dosing of lepirudin. British Journal of Clinical Pharmacology, 2011, 72, 717-717.	2.4	0
86	Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion, 2011, 51, 2237-2243.	1.6	27
87	The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers â€“ two independent studies. Journal of Thrombosis and Haemostasis, 2011, 9, 140-148.	3.8	21
88	Screening for lupus anticoagulant: improving the performance of the lupus-sensitive PTT-LA. International Journal of Laboratory Hematology, 2011, 33, 168-175.	1.3	2
89	Inhibitory Spleen-Derived Anti-ADAMTS13 Antibodies Are Characterized by a Limited Number of Variable Heavy Chain CDR3 Signatures in Patients with Relapsing Acquired Thrombotic Thromobocytopenic Purpura. Blood, 2011, 118, 194-194.	1.4	1
90	Low-dose recombinant factor VIIa for massive bleeding: A single centre observational cohort study with 73 patients. Swiss Medical Weekly, 2011, 141, w13213.	1.6	12

#	Article	IF	Citations
91	Long-Term Outcomes of Renal Function in Patients with TTP Associated with Severe ADAMTS13 Deficiency. Blood, 2011, 118, 2215-2215.	1.4	0
92	Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, 115, 1500-1511.	1.4	477
93	Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolyticâ€uremic syndromes. American Journal of Hematology, 2010, 85, 844-847.	4.1	75
94	RumpelÃ¢Â€Â“Leede sign in thrombocytopenia due to EpsteinÃ¢Â€Â“Barr virus-induced mononucleosis. British Journal of Haematology, 2010, 148, 2-2.	2.5	14
95	D-Dimers Predict Stroke Subtype when Assessed Early. Cerebrovascular Diseases, 2010, 29, 82-86.	1.7	58
96	A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2010, 116, 726-726.	1.4	4
97	Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired Î±2-antiplasmin deficiency associated with AL amyloidosis. Thrombosis and Haemostasis, 2009, 102, 1285-1287.	3.4	7
98	Frequency and Significance of HIV Infection among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura. Clinical Infectious Diseases, 2009, 48, 1129-1137.	5.8	48
99	Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation. British Journal of Haematology, 2009, 144, 136-137.	2.5	11
100	Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 873-887.	1.6	99
101	Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion, 2009, 49, 1092-1101.	1.6	73
102	Variability of antiâ€PF4/heparin antibody results obtained by the rapid testing system IDâ€H/PF4â€PaGIA. Journal of Thrombosis and Haemostasis, 2009, 7, 1649-1655.	3.8	29
103	Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2009, 7, 1755-1756.	3.8	1
104	Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. Blood, 2009, 113, 2402-2409.	1.4	43
105	A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13. Annals of Hematology, 2008, 87, 663-666.	1.8	23
106	Sporadic bloody diarrhoeaâ€associated thrombotic thrombocytopenic purpuraâ€haemolytic uraemic syndrome: an adult and paediatric comparison. British Journal of Haematology, 2008, 141, 696-707.	2.5	50
107	The Oklahoma Thrombotic Thrombocytopenic Purpuraâ€“Hemolytic Uremic Syndrome Registry: the Swiss connection. European Journal of Haematology, 2008, 80, 277-286.	2.2	40
108	Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica, 2008, 93, 172-177.	3.5	44

#	Article	IF	Citations
109	Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature. Thrombosis and Haemostasis, 2008, 99, 416-426.	3.4	81
110	Characterization of Five Homozygous ADAMTS13 Mutations in Hereditary Thrombotic Thrombocytopenic Purpura â€“ Towards a Phenotype-Genotype Correlation?. Blood, 2008, 112, 274-274.	1.4	9
111	Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature: only a part of the story. Reply to E. J. Favaloro. Thrombosis and Haemostasis, 2008, 99, 1123.	3.4	0
112	Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica, 2007, 92, 936-943.	3.5	75
113	Factor XIII in severe sepsis and septic shock. Thrombosis Research, 2007, 119, 311-318.	1.7	25
114	Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica, 2007, 92, 95-100.	3.5	341
115	Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. Thrombosis and Haemostasis, 2007, 98, 1200-1207.	3.4	29
116	Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2007, 5, 866-867.	3.8	72
117	ADAMTSâ€13, von Willebrand factor and related parameters in severe sepsis and septic shock. Journal of Thrombosis and Haemostasis, 2007, 5, 2284-2290.	3.8	153
118	Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).. Blood, 2007, 110, 1311-1311.	1.4	3
119	The ADAMTS13 Gene as the Immunological Culprit in Acute Acquired TTP - First Evidence of Genetic Out-Breeding Depression in Humans.. Blood, 2007, 110, 277-277.	1.4	6
120	Sporadic Bloody Diarrhea-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults in Oklahoma: Comparison to Adults with Severe Adamts13 Deficiency and to Children with Typical HUS.. Blood, 2007, 110, 1317-1317.	1.4	2
121	Beta2-Glycoprotein I: Implications for a Regulatory Role in Thrombotic Thrombocytopenic Purpura.. Blood, 2007, 110, 278-278.	1.4	19
122	Role of Microparticles in Thrombin Generation in Patients at Risk for Atherothrombosis.. Blood, 2007, 110, 1624-1624.	1.4	0
123	Clinical Outcomes in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (TTP) Who Received Platelet Transfusions (PT).. Blood, 2007, 110, 1302-1302.	1.4	0
124	Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Medical Weekly, 2007, 137, 518-24.	1.6	23
125	A common origin of the 4143insA ADAMTS13 mutation. Thrombosis and Haemostasis, 2006, 96, 3-6.	3.4	74
126	Treatment of thrombotic thrombocytopenic purpura. Vox Sanguinis, 2006, 90, 245-254.	1.5	57

#	Article	IF	Citations
127	Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. Journal of Thrombosis and Haemostasis, 2006, 4, 1146-1148.	3.8	89
128	A new tool to further explore the role of ADAMTS-13 in health and disease. Journal of Thrombosis and Haemostasis, 2006, 4, 952-954.	3.8	2
129	Hemophilia A Pseudoaneurysm in a Patient with High Responding Inhibitors Complicating Total Knee Arthroplasty: Embolization: A Cost-Reducing Alternative to Medical Therapy. CardioVascular and Interventional Radiology, 2006, 29, 1132-1135.	2.0	21
130	ADAMTS13 activity in sickle cell disease. American Journal of Hematology, 2006, 81, 492-498.	4.1	54
131	Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 1067-1067.	1.4	3
132	Predicting Risk for Relapse in Patients Who Have Recovered from Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 91-91.	1.4	4
133	Pancreatitis Preceding Acute Episodes of Thrombotic Thrombocytopenic Purpura: Report of Five Patients with a Systematic Review of Published Reports.. Blood, 2006, 108, 1058-1058.	1.4	9
134	Absolute and Relative Blood Lymphocyte Subset Counts before and during Treatment of Patients with Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 3953-3953.	1.4	0
135	Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood, 2005, 105, 542-544.	1.4	152
136	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267.	1.4	275
137	Usefulness of the D-dimer/fibrinogen ratio to predict deep venous thrombosis. Journal of Thrombosis and Haemostasis, 2005, 3, 385-387.	3.8	24
138	Thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2005, 3, 1663-1675.	3.8	159
139	More on: thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2005, 3, 1549-1549.	3.8	3
140	The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. Journal of Thrombosis and Haemostasis, 2005, 3, 1432-1436.	3.8	305
141	Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS13 deficiency?. Thrombosis and Haemostasis, 2005, 94, 1186-1189.	3.4	12
142	Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thrombosis and Haemostasis, 2004, 91, 276-282.	3.4	50
143	Thrombotic thrombocytopenic purpura. The Hematology Journal, 2004, 5, S6-S11.	1.4	4
144	Potential role of d-dimer to rule in pulmonary embolism: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2004, 2, 369-370.	3.8	1

#	Article	IF	Citations
145	Von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Seminars in Hematology, 2004, 41, 75-82.	3.4	79
146	Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Seminars in Hematology, 2004, 41, 48-59.	3.4	39
147	Thrombotic thrombocytopenic purpura: advances in pathophysiology, diagnosis, and treatmentâ€"introduction. Seminars in Hematology, 2004, 41, 1-3.	3.4	14
148	Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood, 2004, 103, 4195-4197.	1.4	61
149	Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood, 2004, 103, 4514-4519.	1.4	204
150	Long-Term Follow-Up of 21 Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Severe ADAMTS13 Deficiency: Demonstration of Persistent ADAMTS13 Deficiency and Neurocognitive Abnormalities.. Blood, 2004, 104, 856-856.	1.4	2
151	The Incidence of TTP-HUS: Racial Disparity among Patients with Severe ADAMTS13 Deficiency.. Blood, 2004, 104, 857-857.	1.4	11
152	Thrombotic Thrombocytopenic Purpura (TTP) and Systemic Lupus Erythematosus (SLE): Distinct but Potentially Overlapping Syndromes.. Blood, 2004, 104, 858-858.	1.4	3
153	Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults Following a Prodrome of Bloody Diarrhea.. Blood, 2004, 104, 859-859.	1.4	0
154	Factor V Leiden Is Not a Risk Factor for Thrombotic Microangiopathies without Severe ADAMTS13 Deficiency.. Blood, 2004, 104, 850-850.	1.4	0
155	ADAMTS13 Activity in Sickle Cell Disease: A Role in the Development of Clinical Vaso-Occlusion?.. Blood, 2004, 104, 3738-3738.	1.4	0
156	Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica, 2004, 89, 320-4.	3.5	46
157	Accuracy of d-dimer/fibrinogen ratio to predict pulmonary embolism: a prospective diagnostic study. Journal of Thrombosis and Haemostasis, 2003, 1, 708-713.	3.8	82
158	Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. Journal of Thrombosis and Haemostasis, 2003, 1, 1882-1887.	3.8	95
159	ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. British Journal of Haematology, 2003, 120, 821-824.	2.5	89
160	Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. American Journal of Medicine, 2003, 114, 528-536.	1.5	72
161	Elevated nucleosome levels in systemic inflammation and sepsis*. Critical Care Medicine, 2003, 31, 1947-1951.	0.9	715
162	The von Willebrand Factor-Cleaving Protease (ADAMTS-13) and the Diagnosis of Thrombotic Thrombocytopenic Purpura (TTP). Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 417-421.	0.3	18

#	Article	IF	Citations
163	Title is missing!. Blood Coagulation and Fibrinolysis, 2003, 14, 313.	1.0	0
164	ADAMTS13 activity in thrombotic thrombocytopenic purpuraâ€“hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 2003, 102, 60-68.	1.4	649
165	Discrepant activity levels of von Willebrand factorâ€“cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura. Blood, 2003, 102, 1148-1148.	1.4	4
166	Hemostatic risk factors in ischemic stroke. Thrombosis and Haemostasis, 2003, 90, 1094-1099.	3.4	13
167	Assays of von Willebrand Factor- Cleaving Protease: A Test for Diagnosis of Familial and Acquired Thrombotic Thrombocytopenic Purpura. Seminars in Thrombosis and Hemostasis, 2002, 28, 167-172.	2.7	25
168	C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction. Critical Care Medicine, 2002, 30, 1722-1728.	0.9	634
169	Von Willebrand factorâ€“cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood, 2002, 100, 710-713.	1.4	343
170	Cloning, expression, and functional characterization of the von Willebrand factorâ€“cleaving protease (ADAMTS13). Blood, 2002, 100, 3626-3632.	1.4	216
171	Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis, 2002, 161, 261-267.	0.8	61
172	Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thrombosis Research, 2002, 105, 441-446.	1.7	49
173	Prekallikrein deficiency. Thrombosis Research, 2002, 105, 463-470.	1.7	60
174	Reply to Rebuttal: von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome. Thrombosis and Haemostasis, 2002, 87, 549-550.	3.4	2
175	Platelets: Thrombotic Thrombocytopenic Purpura. Hematology American Society of Hematology Education Program, 2002, 2002, 315-334.	2.5	58
176	Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency. Swiss Medical Weekly, 2002, 132, 443-8.	1.6	29
177	Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Practice and Research in Clinical Haematology, 2001, 14, 437-454.	1.7	217
178	Increased fibrin monomer plasma concentration in stable coronary artery disease in patients without oral anticoagulation. Atherosclerosis, 2001, 157, 417-422.	0.8	4
179	Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet, The, 2001, 358, 840.	13.7	12
180	Genetic Predisposition to Bleeding during Oral Anticoagulant Therapy: Evidence for Common Founder Mutations (FIXVal-10 and FIXThr-10) and an Independent CpG Hotspot Mutation (FIXThr-10). Thrombosis and Haemostasis, 2001, 85, 454-457.	3.4	25

#	Article	IF	Citations
181	Von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome. Thrombosis and Haemostasis, 2001, 85, 975-978.	3.4	64
182	Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasminâ€“Î±2-antiplasmin complex is an independent predictor of coronary re-events. Blood Coagulation and Fibrinolysis, 2001, 12, 17-24.	1.0	15
183	Rapid D-dimer testing and pre-test clinical probability in the exclusion of deep venous thrombosis in symptomatic outpatients. Blood Coagulation and Fibrinolysis, 2001, 12, 165-170.	1.0	43
184	Partial amino acid sequence of purified von Willebrand factorâ€“cleaving protease. Blood, 2001, 98, 1654-1661.	1.4	375
185	Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. British Journal of Haematology, 2001, 113, 100-102.	2.5	70
186	Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. British Journal of Haematology, 2001, 113, 649-651.	2.5	95
187	Protein Z in ischaemic stroke. British Journal of Haematology, 2001, 114, 169-173.	2.5	59
188	Acquired deficiency of von Willebrand factorâ€cleaving protease in a patient suffering from acute systemic lupus erythematosus. Rheumatology, 2001, 40, 940-942.	1.9	24
189	Protein C Replacement in Severe Meningococcemia: Rationale and Clinical Experience. Clinical Infectious Diseases, 2001, 32, 1338-1346.	5.8	74
190	Splenectomy in thrombotic thrombocytopenic purpura. , 2000, 64, 79-79.		2
191	Mycobacterium genavense infection in a patient with long-standing chronic lymphocytic leukaemia. Journal of Internal Medicine, 2000, 248, 343-348.	6.0	38
192	High Molecular Weight Kininogen Is Cleaved by FXIa at Three Sites: Arg409-Arg410, Lys502-Thr503 and Lys325-Lys326. Thrombosis and Haemostasis, 2000, 83, 709-714.	3.4	15
193	Agreement of D-dimer Results Measured by a Rapid ELISA (VIDAS) before and after Storage during 24 h or Transportation of the Original Whole Blood Samples. Thrombosis and Haemostasis, 2000, 83, 177-178.	3.4	15
194	Haemolyticâ€uraemic syndrome and thrombotic thrombocytopenic purpuraâ€”new insights into underlying biochemical mechanisms. Nephrology Dialysis Transplantation, 2000, 15, 1112-1114.	0.7	35
195	Assay of von Willebrand Factor (vWF)-cleaving Protease Based on Decreased Collagen Binding Affinity of Degraded vWF. Thrombosis and Haemostasis, 1999, 82, 1386-1389.	3.4	310
196	Recovery and Half-Life of von Willebrand Factor-Cleaving Protease after Plasma Therapy in Patients with Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 1999, 81, 8-13.	3.4	203
197	Performance of a New Fibrin Monomer Assay to Exclude Deep Vein Thrombosis in Symptomatic Outpatients. Thrombosis and Haemostasis, 1999, 81, 50-53.	3.4	18
198	Von Willebrand Factor in Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 1999, 82, 592-600.	3.4	28

#	Article	IF	Citations
199	Coagulation Factors II, V, VII, and X, Prothrombin Gene 20210Gâ†'A Transition, and Factor V Leiden in Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1020-1025.	2.4	97
200	FATAL FRESH FROZEN PLASMA INFUSION CONTAINING HPA-1a ALLOANTIBODIES. British Journal of Haematology, 1999, 106, 258-259.	2.5	11
201	IFNÎ± treatment in systemic mastocytosis. Annals of Hematology, 1999, 78, 483-484.	1.8	26
202	New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review. European Journal of Pediatrics, 1999, 158, 883-887.	2.7	28
203	Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet, The, 1999, 353, 351-354.	13.7	200
204	Fibrinogen Milano XIII (AÎ± 19 Argâ†'Gly). Thrombosis Research, 1999, 96, 399-405.	1.7	6
205	Fibrinogens Bern IV, Bern V and Milano XI. Blood Coagulation and Fibrinolysis, 1999, 10, 93-100.	1.0	11
206	16 Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Best Practice and Research: Clinical Haematology, 1998, 11, 509-514.	1.1	41
207	Protein Z in healthy human individuals and in patients with a bleeding tendency. British Journal of Haematology, 1998, 102, 1219-1223.	2.5	41
208	von Willebrand Factorâ€"Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolyticâ€"Uremic Syndrome. New England Journal of Medicine, 1998, 339, 1578-1584.	27.0	1,717
209	CapnocytophagaÂ canimorsusSepsis. New England Journal of Medicine, 1998, 339, 1827-1827.	27.0	19
210	SimpliRED D-dimer Assay: Comparability of Capillary and Citrated Venous Whole Blood, Between-assay Variability, and Performance of the Test for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients. Thrombosis and Haemostasis, 1998, 79, 1217-1219.	3.4	44
211	Acquired Deficiency of von Willebrand Factor-Cleaving Protease in a Patient With Thrombotic Thrombocytopenic Purpura. Blood, 1998, 91, 2839-2846.	1.4	324
212	Influence of Low Molecular Weight Heparin and Low Molecular Weight Dextran Sulfate on the Inhibition of Coagulation Factor XIa by Serpins. Thrombosis and Haemostasis, 1998, 80, 82-86.	3.4	21
213	Dural puncture and activated protein C resistance: risk factors for cerebral venous sinus thrombosis. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 63, 351-356.	1.9	77
214	Phenprocoumon-Induced Hepatitis Delaying Precise Diagnosis in a Thrombophilic Patient With Activated Protein C Resistance Due to Factor V R506Q Mutation. American Journal of Medicine, 1997, 103, 437-439.	1.5	7
215	Deficient Activity of von Willebrand Factorâ€"Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic Purpura. Blood, 1997, 89, 3097-3103.	1.4	536
216	Subcutaneous low-molecular-weight heparin for treatment of Trousseauâ€™s syndrome. Annals of Hematology, 1997, 75, 165-167.	1.8	14

#	Article	IF	Citations
217	Venous thrombosis after Caesarean section in a young woman with homozygous APC resistance and type I protein S deficiency. European Journal of Haematology, 1997, 58, 127-129.	2.2	4
218	Plasma Protein C Inhibitor Is Elevated in Survivors of Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 114-118.	2.4	28
219	Activation of the Contact System in Patients With Sepsis and With Septic Shock. Blood, 1997, 89, 3893-3794.	1.4	0
220	Fibrinogen Claro â€" Another dysfunctional fibrinogen variant with Î³ 275 Arginine â†' Histidine substitution. Thrombosis Research, 1996, 81, 145-150.	1.7	5
221	Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood, 1996, 87, 4223-4234.	1.4	858
222	Binding of calcium ions and their effect on clotting of fibrinogen Milano III, a variant with truncated A??-chains. Blood Coagulation and Fibrinolysis, 1996, 7, 331-335.	1.0	6
223	SEVERE OSTEOPOROSIS DUE TO SYSTEMIC MAST CELL DISEASE: SUCCESSFUL TREATMENT WITH INTERFERON ALPHA-2B. Rheumatology, 1996, 35, 898-900.	1.9	66
224	Biocompatibility in transfusion medicine. Transfusion Science, 1996, 17, 481-488.	0.6	6
225	Normal Binding of Calcium to Five Fibrinogen Variants with Mutations in the Carboxy Terminal Part of the Î³-Chain. Thrombosis and Haemostasis, 1996, 76, 377-383.	3.4	7
226	Plasminogen Deficiency: An Additional Risk Factor for Thrombosis in a Family with Factor V R506Q Mutation?. Thrombosis and Haemostasis, 1996, 76, 475-476.	3.4	9
227	IN VITRO EVALUATION OF THE EFFICACY AND BIOCOMPATIBILITY OF NEW, SYNTHETIC ABO IMMUNOABSORBENTS. Transplantation, 1995, 60, 425-429.	1.0	32
228	No association of APC resistance with myocardial infarction. Blood Coagulation and Fibrinolysis, 1995, 6, 456-459.	1.0	35
229	The novel acceptor splice site mutation 11396(G->A) in the factor XII gene causes a truncated transcript in cross-reacting material negative patients. Human Molecular Genetics, 1995, 4, 1235-1237.	2.9	27
230	A new substitution, gamma 358 Ser-->Cys, in fibrinogen Milano VII causes defective fibrin polymerization. Blood, 1994, 84, 1874-1880.	1.4	20
231	Mucocutaneous bleeding, a rare but severe complication in nephrosialidosis. European Journal of Pediatrics, 1994, 153, 703-704.	2.7	1
232	Cold Agglutinin Syndrome and Liver Transplantation. Vox Sanguinis, 1994, 67, 85-85.	1.5	9
233	Binding of Î±-thrombin to fibrin depends on the quality of the fibrin network. Biochemical Journal, 1994, 298, 157-163.	3.7	31
234	Low molecular weight heparinâ€induced thrombocytopenia and skin necrosis distant from injection sites. European Journal of Haematology, 1994, 53, 61-63.	2.2	24

#	Article	IF	Citations
235	Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353–>Pro leading to loss of a kallikrein cleavage site. Blood, 1994, 84, 1173-1181.	1.4	1
236	Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7503-7507.	7.1	78
237	Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. British Journal of Haematology, 1993, 85, 528-532.	2.5	157
238	Functional Characterization of a Variant Prekallikrein (PK ZÃ¼rich). Thrombosis and Haemostasis, 1993, 70, 427-432.	3.4	12
239	Fibrinogen Bern I: substitution gamma 337 Asn-->Lys is responsible for defective fibrin monomer polymerization. Blood, 1993, 82, 2104-2108.	1.4	9
240	Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagulation and Fibrinolysis, 1992, 3, 555-562.	1.0	35
241	Determination of thrombin-antithrombin-III-complex is not a suitable screening test for detecting deficiency of protein C or protein S. Thrombosis Research, 1992, 66, 775-777.	1.7	3
242	Functional Characterization of a Variant Factor XII (F XII Locarno) in a Cross Reacting Material Positive F XII Deficient Plasma. Thrombosis and Haemostasis, 1992, 67, 219-225.	3.4	11
243	Immunogold labelling of human von Willebrand factor adsorbed to collagen. Blood Coagulation and Fibrinolysis, 1991, 2, 441-446.	1.0	3
244	Major Coagulation Disorders when using Aprotinin - Observations on a Case. Thoracic and Cardiovascular Surgeon, 1991, 39, 196-198.	1.0	6
245	Thromboembolism and Bleeding Tendency in Congenital Factor XII DeficienCy - A Study on 74 Subjects from 14 Swiss Families. Thrombosis and Haemostasis, 1991, 65, 117-121.	3.4	146
246	Purified Factor XII Has a Higher Specific Activity than the Parent Molecule in Plasma. Thrombosis and Haemostasis, 1991, 65, 169-173.	3.4	3
247	Inferior vena cava thrombosis in a child with nephroblastoma and combined deficiency of antithrombin III and free protein S. Blut, 1990, 61, 295-297.	1.2	4
248	Malondialdehyde formation by blood platelets: A diagnostic test to assess acetylsalicylic acid induced thrombocytopathy?. Thrombosis Research, 1990, 59, 89-95.	1.7	0
249	A quantitative dot immunobinding assay for coagulation factor XII in plasma. Journal of Immunological Methods, 1990, 130, 133-140.	1.4	9
250	Decreased Free Protein S Levels in Polycythemia Vera. Thrombosis and Haemostasis, 1990, 64, 177-178.	3.4	7
251	Contact phase of blood coagulation is not activated in edema of high altitude. Journal of Applied Physiology, 1989, 67, 1336-1340.	2.5	18
252	How high is the true fibrinogen content of fibrinogen standards?. Thrombosis Research, 1989, 56, 583-592.	1.7	17

#	Article	IF	Citations
253	Comments on â€˜quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibodyâ€™ by Reddigari and Kaplan. Journal of Immunological Methods, 1989, 125, 291-292.	1.4	2
254	Purified Human Plasma Kallikrein Does Not Stimulate but Primes Neutrophils for Superoxide Production. Thrombosis and Haemostasis, 1989, 62, 1121-1125.	3.4	23
255	Virus-inactivated factor VIII concentrate prevents postoperative bleeding in a patient with von Willebrand's disease. Transfusion, 1988, 28, 489-492.	1.6	5
256	Tryptase from human mast cells does not activate purified human Hageman Factor. Clinical and Experimental Allergy, 1988, 18, 151-156.	2.9	4
257	Heparin-dependent in vitro aggregation of normal platelets by plasma of a patient with heparin-induced skin necrosis: specific diagnostic test for a rare side effect. American Journal of Medicine, 1988, 85, 721-724.	1.5	32
258	Immunoblotting studies of the molecular forms of protein C in plasma. Thrombosis Research, 1988, 52, 33-43.	1.7	61
259	Haemorrhagic Shock Nine Days after Extracorporeal Shock Wave Lithotripsy in a Patient with Haemophilia B. Thrombosis and Haemostasis, 1988, 60, 532.	3.4	3
260	Detection and Quantitation of Cleaved and Uncleaved High Molecular Weight Kininogen in Plasma by Ligand Blotting with Radiolabeled Plasma Prekallikrein or Factor XI. Thrombosis and Haemostasis, 1988, 59, 151-161.	3.4	33
261	Immunoblotting Studies of Coagulation Factor XII, Plasma Prekallikrein, and High Molecular Weight Kininogen. Seminars in Thrombosis and Hemostasis, 1987, 13, 106-114.	2.7	13
262	DETECTION AND QUANTITATION OF CLEAVED AND UNCLEAVED HIGH MOLECULAR WEIGHT KININOGEN IN PLASMA BY LIGAND BLOTTING WITH RADIOLABELED PLASMA PREKALLIKREIN OR FACTOR XI. Thrombosis and Haemostasis, 1987, 58, 0051.	3.4	0
263	AUTOACTIVATION OF HUMAN PLASMA PREKALLIKREIN. , 1987, 58, 0099.		1
264	Quantitative immunoblotting assay of blood coagulation factor XII. Thrombosis Research, 1986, 41, 747-759.	1.7	23
265	Enhanced specificity of immunoblotting using radiolabeled antigen overlay: Studies of blood coagulation factor XII and prekallikrein in plasma. Analytical Biochemistry, 1986, 156, 118-125.	2.4	30
266	Heparin Cofactor II: Purification and Antibody Production. Thrombosis and Haemostasis, 1986, 55, 019-023.	3.4	9
267	Quantitative Immunoblotting of Plasma and Platelet Protein S. Thrombosis and Haemostasis, 1986, 56, 382-386.	3.4	17
268	Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood, 1986, 68, 455-462.	1.4	4
269	Methodology and Clinical Significance of Heparin Cofactor II. Seminars in Thrombosis and Hemostasis, 1985, 11, 342-346.	2.7	5
270	Treatment with stanozolol before thrombolysis in patients with arterial occlusions. Thrombosis Research, 1985, 37, 529-532.	1.7	6

#	Article	IF	Citations
271	Cold Promoted Activation and Factor XII, Prekallikrein and C1-Inhibitor. Thrombosis and Haemostasis, 1985, 53, 242-244.	3.4	10
272	Plasma Prekallikrein, Factor XII, Antithrombin III, C1â˜-Inhibitor and Î±2-Macroglobulin in Critically Ill Patients with Suspected Disseminated Intravascular Coagulation (DIC). American Journal of Clinical Pathology, 1984, 82, 396-404.	0.7	64
273	Factor VIII (Procoagulant Activity VIII:C, and Antigen VIII:CAg, Related Antigen VIIIR:Ag and Ristocetin) Tj ETQq1 1 0.784314 rgBT /Ove Coagulation (DIC). American Journal of Clinical Pathology, 1984, 82, 565-572.	0.7	10
274	Prekallikrein Activator - Reply. Thrombosis and Haemostasis, 1984, 52, 366-366.	3.4	0
275	Assay of Factor XII Clotting Activity in Heparinized Plasma. American Journal of Clinical Pathology, 1983, 80, 474-477.	0.7	4
276	The Amidolytic Prekallikrein (PK) Determination: Enhanced PK Activation After Deep-Freezing of Patients' Plasmas. Thrombosis and Haemostasis, 1983, 49, 249-249.	3.4	1
277	Monitoring of Heparin Treatment. Comparison between Thrombin Time, Activated Partial Thromboplastin Time, and Plasma Heparin Concentration, and Analysis of the Behavior of Antithrombin III. American Journal of Clinical Pathology, 1980, 74, 68-73.	0.7	38